These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15115189)

  • 1. Role of the cardiologist: clinical aspects of managing erectile dysfunction.
    Hutter AM
    Clin Cardiol; 2004 Apr; 27(4 Suppl 1):I3-7. PubMed ID: 15115189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.
    Sommer F; Schulze W
    World J Urol; 2005 Dec; 23(6):385-92. PubMed ID: 16273418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
    Kloner RA
    Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.
    Thadani U; Smith W; Nash S; Bittar N; Glasser S; Narayan P; Stein RA; Larkin S; Mazzu A; Tota R; Pomerantz K; Sundaresan P
    J Am Coll Cardiol; 2002 Dec; 40(11):2006-12. PubMed ID: 12475462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erectile dysfunction and cardiovascular considerations: managing patients effectively with phosphodiesterase type 5 inhibitors.
    Hutter AM
    Clin Cardiol; 2004 Apr; 27(4 Suppl 1):I1-2. PubMed ID: 15115188
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters.
    Kloner RA
    Clin Cardiol; 2004 Apr; 27(4 Suppl 1):I20-5. PubMed ID: 15115192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
    Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
    Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vardenafil: a review of its use in erectile dysfunction.
    Keating GM; Scott LJ
    Drugs; 2003; 63(23):2673-703. PubMed ID: 14636086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease.
    Archer SL; Gragasin FS; Webster L; Bochinski D; Michelakis ED
    Drugs Aging; 2005; 22(10):823-44. PubMed ID: 16245957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
    Carson CC
    Am J Cardiol; 2005 Dec; 96(12B):37M-41M. PubMed ID: 16387565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction.
    Kendirci M; Bivalacqua TJ; Hellstrom WJ
    Expert Opin Pharmacother; 2004 Apr; 5(4):923-32. PubMed ID: 15102574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors.
    Jackson G
    Am J Cardiol; 2005 Dec; 96(12B):32M-36M. PubMed ID: 16387564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
    Patel MD; Katz SD
    Am J Cardiol; 2005 Dec; 96(12B):47M-51M. PubMed ID: 16387567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles.
    Seftel AD
    Clin Cardiol; 2004 Apr; 27(4 Suppl 1):I14-19. PubMed ID: 15115191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of PDE5 inhibitors.
    Rashid A
    Clin Cornerstone; 2005; 7(1):47-56. PubMed ID: 16156423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
    Vickers MA; Satyanarayana R
    Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erectile dysfunction in the cardiac patient.
    Kloner RA
    Curr Urol Rep; 2003 Dec; 4(6):466-71. PubMed ID: 14622500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
    Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
    J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.